Study finds that the quality of psychedelic experience from psilocybin can predict how effective therapy will be for a patient being treated for treatment-resistant depression.
Results of a study done by the Psychedelic Research Group at the Imperial College London were published in Frontiers of Pharmacology. The study showed that the quality of the psychedelic experience brought on by psilocybin predicted how effective the patient’s therapy was for treatment-resistant depression (TRD).
Psychedelic Science Review is working to bring cutting-edge science in the field of psychedelics to the public in the most accessible, thorough and accurate way possible. Join our communities on Facebook, Twitter, LinkedIn and Instagram and share our content with your network to help us bring scientifically-backed information about psychedelics to the world.
NEW! Shop the PSR Supporter Store to show your support for psychedelic science.